YM 796
Latest Information Update: 30 Jun 2000
At a glance
- Originator Yamanouchi
- Class Neuroprotectants; Nootropics
- Mechanism of Action Muscarinic M1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Dementia
Most Recent Events
- 30 Jun 2000 Discontinued-I for Alzheimer's disease in Germany (PO)
- 30 Jun 2000 Discontinued-II for Dementia in Japan (PO)
- 24 Sep 1998 Phase-II clinical trials for Dementia in Japan (PO)